Stuart Smalheiser, MD
Cardiovascular Disease · Beaufort, SCNPI 1427126663
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,000 of the $45,175 with a category attached, or 77.5%. Shimadzu Precision Instruments, Inc. accounts for 77.5% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $22,775, 2.9 times the $7,974 reported in 2019. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $215.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shimadzu Precision Instruments, Inc.$35K
- Boehringer Ingelheim$7K
- Abbott$2K
- CMS Imaging, Inc.$561
- Amgen$121
- E.r. Squibb & Sons, L.L.C.$98
- plus $352 from 11 others
What the payments were for
- Consulting fees$35,00077%
- Speaking & faculty fees$7,24516%
- Travel & lodging$810%
- Food & beverage$2,7996%
- Gifts$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shimadzu Precision Instruments, Inc. | 2 | $35,000 |
| Boehringer Ingelheim | 9 | $7,416 |
| Abbott | 159 | $1,626 |
| CMS Imaging, Inc. | 6 | $561 |
| Amgen | 5 | $121 |
| E.r. Squibb & Sons, L.L.C. | 7 | $98 |
| Novartis | 3 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $56 |
| AstraZeneca | 3 | $39 |
| Biotronik Inc. | 2 | $36 |
| Johnson & Johnson | 3 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Boston Scientific | 2 | $29 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Shockwave Medical, Inc | 1 | $15 |
| Vital Connect, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRADAXA$7,245
How this compares
$45,175 in reported general payments places this provider in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 897 | $1,146,298 |
| EntrestoSacubitril/Valsartan | 100 | $115,105 |
| XareltoRivaroxaban | 71 | $98,594 |
| FarxigaDapagliflozin Propanediol | 62 | $80,482 |
| Repatha SureclickEvolocumab | 46 | $53,008 |
| MultaqDronedarone Hcl | 20 | $28,795 |
| JardianceEmpagliflozin | 21 | $17,068 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 34 | $13,243 |
| Praluent PenAlirocumab | 17 | $12,371 |
| Rosuvastatin Calcium | 500 | $7,622 |
| Digoxin | 295 | $7,421 |
| Metoprolol Succinate | 462 | $6,775 |
| Flecainide Acetate | 143 | $5,859 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 171 | $4,946 |
| Ranolazine ErRanolazine | 63 | $3,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $58 | $115,105100 claims |
| Johnson & JohnsonXarelto | $35 | $98,59471 claims |
| AstraZenecaFarxiga | $39 | $80,48262 claims |
| Sanofi-aventis U.S. LLCMultaq | $16 | $28,79520 claims |
| Boehringer IngelheimJardiance | $7,416 | $17,06821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Beaufort
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
- Christopher SalmonGreenville$54K
- Ricky HendersonAnderson$52K
- Geetha PintoCharleston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.